logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11413261 B1

PDFFull Text
Date of Patent:
Aug. 16, 2022

Filed:

Nov. 22, 2019

Pharmaceutical composition for treating cancer comprising lactate metal salt

Applicant:

Metimedi Pharmaceuticals Co., Ltd, Incheon, KR;

Inventors:

Hwan Mook Kim, Daejeon, KR;

Keun Yeong Jeong, Seoul, KR;

Jae Jun Sim, Seoul, KR;

Yeong Su Jang, Incheon, KR;

Assignee:

METIMEDI PHARMACEUTICALS CO., LTD, Uiwang-si, KR;

Attorney:

ArentFox Schiff LLP

Primary Examiner:

James D Anderson

Int. Cl.
CPC ...
A61K 31/19 (2006.01); A61K 31/436 (2006.01); A61K 31/404 (2006.01); A61K 31/4745 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 33/34 (2006.01); A61K 9/70 (2006.01); A61K 9/08 (2006.01); A61K 31/191 (2006.01); A61K 33/30 (2006.01); A61K 33/04 (2006.01); A61K 33/06 (2006.01); A61K 9/48 (2006.01); A23L 33/00 (2016.01); A23L 33/16 (2016.01); A61K 31/337 (2006.01); A61K 31/44 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/555 (2006.01); A61K 39/395 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/19 (2013.01); A23L 33/16 (2016.08); A23L 33/30 (2016.08); A61K 9/00 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); A61K 9/08 (2013.01); A61K 9/48 (2013.01); A61K 9/70 (2013.01); A61K 31/191 (2013.01); A61K 31/337 (2013.01); A61K 31/404 (2013.01); A61K 31/436 (2013.01); A61K 31/44 (2013.01); A61K 31/4745 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/555 (2013.01); A61K 33/04 (2013.01); A61K 33/06 (2013.01); A61K 33/30 (2013.01); A61K 33/34 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); A23V 2002/00 (2013.01); A61N 2005/1098 (2013.01);
Abstract

The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer matastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention as disclosed inhibit the growth of cancer cells and induce the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibit the expression of factors inducing resistance against radiation exposure, while having no side effects. Therefore, the lactate metal salt can be widely utilized in a more effective anti-cancer therapy.

Find Patent Forward Citations

Loading…